Why is the approval of Utebzi (tebipenem pivoxil) significant for Spero Therapeutics (NASDAQ:SPRO) and GSK (NYSE:GSK)?

Utebzi (tebipenem pivoxil) is the first and only oral carbapenem antibiotic approved by the FDA for the treatment of complicated urinary tract infections (cUTIs) in adults. This approval provides a vital outpatient treatment option for patients who previously required intravenous therapy due to limited oral alternatives.

What does the Phase 3 PIVOT-PO trial tell us about the efficacy of Utebzi (tebipenem pivoxil)?

The Phase 3 PIVOT-PO trial demonstrated that Utebzi (tebipenem pivoxil) is non-inferior to intravenous imipenem-cilastatin. The study reported an overall success rate of 58.5% for the oral treatment group compared to 60.2% for the intravenous group.

Which patients are indicated for Utebzi (tebipenem pivoxil) by Spero Therapeutics (NASDAQ:SPRO)?

Utebzi (tebipenem pivoxil) is indicated for adult patients with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain susceptible pathogens, specifically those who have limited or no alternative oral treatment options.

When will Utebzi (tebipenem pivoxil) be available for use?

Spero Therapeutics (NASDAQ:SPRO) and GSK (NYSE:GSK) expect Utebzi (tebipenem pivoxil) to be available to patients in the United States by the end of 2026.

How does the safety profile of Utebzi (tebipenem pivoxil) compare to current standard treatments?

The safety profile of Utebzi (tebipenem pivoxil) was found to be generally similar to that of intravenous imipenem-cilastatin and other carbapenem antibiotics. The most frequently reported adverse events included diarrhea and headache, which were described as mild or moderate and non-serious.

Image for illustrative purposes only. Not a real photo.

FDA approves Utebzi as first oral carbapenem

Written by Heidi Cuthbert Published Jun 17, 2026, 5:54 AM

The U.S. Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil) for the treatment of adult patients with complicated urinary tract infections (cUTIs), including pyelonephritis.
Utebzi is the first and only oral carbapenem antibiotic approved in the U.S. for patients with limited or no alternative oral treatment options.
The approval is supported by the Phase 3 PIVOT-PO trial, which demonstrated that oral Utebzi is non-inferior to intravenous imipenem-cilastatin.

Spero Therapeutics (NASDAQ:SPRO) and GSK (NYSE:GSK) announced on June 17, 2026, that the FDA has granted approval for Utebzi, an oral antibiotic designed for adults with complicated urinary tract infections (cUTIs).

Until this approval, carbapenem antibiotics—the standard of care for severe, resistant infections—were available only through intravenous administration, often requiring hospitalization or the use of infusion centers.

The pivotal Phase 3 PIVOT-PO trial enrolled 1,690 hospitalized patients and met its primary endpoint by demonstrating that 600 mg of oral Utebzi administered every six hours was non-inferior to 500 mg of intravenous imipenem-cilastatin.

Data from the trial showed a 58.5% overall success rate for Utebzi compared to 60.2% for the intravenous therapy, with a safety profile generally consistent with other carbapenem antibiotics.

Following the announcement, Spero Therapeutics' share price was up at $1.65.

This drug is expected to be available for patients in the United States by the end of 2026, offering a new outpatient treatment path for infections caused by susceptible pathogens.